{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:10:11Z","timestamp":1792800611901,"version":"4.5.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,23]],"date-time":"2022-11-23T00:00:00Z","timestamp":1669161600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,23]],"date-time":"2022-11-23T00:00:00Z","timestamp":1669161600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"New National Natural Science Foundation of China","award":["82172856"],"award-info":[{"award-number":["82172856"]}],"id":[{"id":"https:\/\/ror.org\/01h0zpd94","id-type":"ROR","asserted-by":"crossref"}]},{"name":"New National Natural Science Foundation of China","award":["81972805"],"award-info":[{"award-number":["81972805"]}],"id":[{"id":"https:\/\/ror.org\/01h0zpd94","id-type":"ROR","asserted-by":"crossref"}]},{"name":"China National Major Project for New Drug Innovation","award":["2017ZX09304015"],"award-info":[{"award-number":["2017ZX09304015"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Conteltinib (CT-707) is a potent second-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) showing promising anti-tumor activities in preclinical studies. This study aimed to assess the safety, pharmacokinetic (PK), and efficacy of conteltinib in patients with ALK-positive non-small cell lung cancer (NSCLC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this multicenter, single-arm, open-label, first-in-human phase 1 study, conteltinib was taken orally at doses of 50 to 800 mg quaque die (QD) in a dose-escalation phase. If the response was observed in a dose cohort of the dose-escalation phase, dose expansion was started. The primary endpoints were maximum tolerated dose (MTD), dose-limiting toxicity (DLT), and adverse events assessed by investigators.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Between April 13, 2016, and February 8, 2020, 64 ALK-positive NSCLC patients were enrolled, including 41 (64.1%) patients with ALK TKI-na\u00efve and 23 (35.9%) patients who received crizotinib previously. In the dose-escalation phase, 26 patients were treated with conteltinib at doses of 50 mg, 100 mg, 200 mg, 300 mg, 450 mg, 600 mg, and 800 mg QD. One DLT event was reported at the dose of 600 mg. MTD was not reached. Overall, 58 (90.6%) patients experienced treatment-related adverse events (TRAEs) and 9 (14.1%) patients had grade \u2265 3 TRAEs. The most common TRAEs were diarrhea (46 [71.9%]), serum creatinine elevated (29 [45.3%]), aspartate aminotransferase elevated (25 [39.1%]), and nausea (24 [37.5%]). Among 39 ALK TKI-na\u00efve patients, the overall response rate (ORR) was 64.1% (25 of 39; 95% confidence interval [CI], 47.2\u201378.8), median progression-free survival (PFS) was 15.9 months (95% CI, 9.26\u201323.3), and median duration of response (DoR) was 15.0 months (95% CI, 9.06\u201325.8). Among 21 patients who received crizotinib previously, the ORR was 33.3% (7 of 21; 95% CI, 14.6\u201357.0), median PFS was 6.73 months (95% CI, 4.73\u20138.54), and median DoR was 6.60 months (95% CI, 3.77\u201313.3).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this study, conteltinib showed manageable safety profile, favorable PK properties, and anti-tumor activity in advanced ALK-positive NSCLC patients. The recommended phase 2 dose was determined to be 600 mg QD for ALK TKI-na\u00efve patients and 300 mg bis in die (BID)\u00a0for patients who received crizotinib previously.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>ClinicalTrials.gov, NCT02695550.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12916-022-02646-0","type":"journal-article","created":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T13:51:13Z","timestamp":1669297873000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Conteltinib (CT-707) in patients with advanced ALK-positive non-small cell lung cancer: a multicenter, open-label, first-in-human phase 1 study"],"prefix":"10.1186","volume":"20","author":[{"given":"Puyuan","family":"Xing","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dingzhi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinghui","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8685-6744","authenticated-orcid":false,"given":"Yuankai","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,23]]},"reference":[{"issue":"7153","key":"2646_CR1","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/nature05945","volume":"448","author":"M Soda","year":"2007","unstructured":"Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007;448(7153):561\u20136.","journal-title":"Nature."},{"issue":"7511","key":"2646_CR2","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/nature13385","volume":"511","author":"Cancer Genome Atlas Research N","year":"2014","unstructured":"Cancer Genome Atlas Research N. Comprehensive molecular profiling of lung adenocarcinoma. Nature. 2014;511(7511):543\u201350.","journal-title":"Nature."},{"issue":"1","key":"2646_CR3","doi-asserted-by":"publisher","first-page":"R11","DOI":"10.1530\/JME-11-0004","volume":"47","author":"A Barreca","year":"2011","unstructured":"Barreca A, Lasorsa E, Riera L, Machiorlatti R, Piva R, Ponzoni M, et al. Anaplastic lymphoma kinase in human cancer. J Mol Endocrinol. 2011;47(1):R11\u201323.","journal-title":"J Mol Endocrinol"},{"issue":"10","key":"2646_CR4","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/S1470-2045(12)70344-3","volume":"13","author":"DR Camidge","year":"2012","unstructured":"Camidge DR, Bang YJ, Kwak EL, Iafrate AJ, Varella-Garcia M, Fox SB, et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol. 2012;13(10):1011\u20139.","journal-title":"Lancet Oncol"},{"issue":"18","key":"2646_CR5","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1056\/NEJMoa1006448","volume":"363","author":"EL Kwak","year":"2010","unstructured":"Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010;363(18):1693\u2013703.","journal-title":"N Engl J Med"},{"issue":"120","key":"2646_CR6","doi-asserted-by":"publisher","first-page":"120ra117","DOI":"10.1126\/scitranslmed.3003316","volume":"4","author":"R Katayama","year":"2012","unstructured":"Katayama R, Shaw AT, Khan TM, Mino-Kenudson M, Solomon BJ, Halmos B, et al. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers. Sci Transl Med. 2012;4(120):120ra117.","journal-title":"Sci Transl Med"},{"issue":"5","key":"2646_CR7","doi-asserted-by":"publisher","first-page":"e77","DOI":"10.1016\/j.cllc.2016.03.005","volume":"17","author":"YT Lin","year":"2016","unstructured":"Lin YT, Yu CJ, Yang JC, Shih JY. Anaplastic lymphoma kinase (ALK) kinase domain mutation following ALK inhibitor(s) failure in advanced ALK positive non-small-cell lung cancer: analysis and literature review. Clin Lung Cancer. 2016;17(5):e77\u201394.","journal-title":"Clin Lung Cancer"},{"issue":"5","key":"2646_CR8","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1158\/1078-0432.CCR-11-2906","volume":"18","author":"RC Doebele","year":"2012","unstructured":"Doebele RC, Pilling AB, Aisner DL, Kutateladze TG, Le AT, Weickhardt AJ, et al. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin Cancer Res. 2012;18(5):1472\u201382.","journal-title":"Clin Cancer Res"},{"issue":"17","key":"2646_CR9","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1056\/NEJMc1410799","volume":"371","author":"S Giri","year":"2014","unstructured":"Giri S, Patel JK, Mahadevan D. Novel mutations in a patient with ALK-rearranged lung cancer. N Engl J Med. 2014;371(17):1655\u20136.","journal-title":"N Engl J Med"},{"issue":"15","key":"2646_CR10","doi-asserted-by":"publisher","first-page":"4273","DOI":"10.1158\/1078-0432.CCR-13-0318","volume":"19","author":"JF Gainor","year":"2013","unstructured":"Gainor JF, Varghese AM, Ou SH, Kabraji S, Awad MM, Katayama R, et al. ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer. Clin Cancer Res. 2013;19(15):4273\u201381.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"2646_CR11","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1097\/JTO.0b013e318283dcc0","volume":"8","author":"S Kim","year":"2013","unstructured":"Kim S, Kim TM, Kim DW, Go H, Keam B, Lee SH, et al. Heterogeneity of genetic changes associated with acquired crizotinib resistance in ALK-rearranged lung cancer. J Thorac Oncol. 2013;8(4):415\u201322.","journal-title":"J Thorac Oncol"},{"key":"2646_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejca.2021.06.043","volume":"156","author":"YT Lin","year":"2021","unstructured":"Lin YT, Chiang CL, Hung JY, Lee MH, Su WC, Wu SY, et al. Resistance profiles of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced non-small-cell lung cancer: a multicenter study using targeted next-generation sequencing. Eur J Cancer. 2021;156:1\u201311.","journal-title":"Eur J Cancer"},{"issue":"4","key":"2646_CR13","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/S1470-2045(15)00614-2","volume":"17","author":"DW Kim","year":"2016","unstructured":"Kim DW, Mehra R, Tan DSW, Felip E, Chow LQM, Camidge DR, et al. Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial. Lancet Oncol. 2016;17(4):452\u201363.","journal-title":"Lancet Oncol"},{"issue":"6","key":"2646_CR14","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1093\/annonc\/mdy121","volume":"29","author":"S Novello","year":"2018","unstructured":"Novello S, Mazieres J, Oh IJ, de Castro J, Migliorino MR, Helland A, et al. Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study. Ann Oncol. 2018;29(6):1409\u201316.","journal-title":"Ann Oncol"},{"issue":"22","key":"2646_CR15","doi-asserted-by":"publisher","first-page":"2490","DOI":"10.1200\/JCO.2016.71.5904","volume":"35","author":"DW Kim","year":"2017","unstructured":"Kim DW, Tiseo M, Ahn MJ, Reckamp KL, Hansen KH, Kim SW, et al. Brigatinib in patients with crizotinib-refractory anaplastic lymphoma kinase-positive non-small-cell lung cancer: a randomized, multicenter phase II trial. J Clin Oncol. 2017;35(22):2490\u20138.","journal-title":"J Clin Oncol"},{"issue":"12","key":"2646_CR16","doi-asserted-by":"publisher","first-page":"2771","DOI":"10.1158\/1078-0432.CCR-17-2398","volume":"24","author":"L Horn","year":"2018","unstructured":"Horn L, Infante JR, Reckamp KL, Blumenschein GR, Leal TA, Waqar SN, et al. Ensartinib (X-396) in ALK-positive non-small cell lung cancer: results from a first-in-human phase I\/II, multicenter study. Clin Cancer Res. 2018;24(12):2771\u20139.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2646_CR17","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41392-021-00841-8","volume":"7","author":"Y Shi","year":"2022","unstructured":"Shi Y, Fang J, Hao X, Zhang S, Liu Y, Wang L, et al. Safety and activity of WX-0593 (iruplinalkib) in patients with ALK- or ROS1-rearranged advanced non-small cell lung cancer: a phase 1 dose-escalation and dose-expansion trial. Signal Transduct Target Ther. 2022;7(1):25.","journal-title":"Signal Transduct Target Ther"},{"issue":"12","key":"2646_CR18","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1016\/S1470-2045(18)30649-1","volume":"19","author":"BJ Solomon","year":"2018","unstructured":"Solomon BJ, Besse B, Bauer TM, Felip E, Soo RA, Camidge DR, et al. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study. Lancet Oncol. 2018;19(12):1654\u201367.","journal-title":"Lancet Oncol"},{"issue":"12","key":"2646_CR19","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1016\/j.jtho.2021.07.035","volume":"16","author":"DR Camidge","year":"2021","unstructured":"Camidge DR, Kim HR, Ahn MJ, Yang JCH, Han JY, Hochmair MJ, et al. Brigatinib versus crizotinib in ALK inhibitor-naive advanced ALK-positive NSCLC: final results of phase 3 ALTA-1L trial. J Thorac Oncol. 2021;16(12):2091\u2013108.","journal-title":"J Thorac Oncol"},{"issue":"8","key":"2646_CR20","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1016\/j.annonc.2020.04.478","volume":"31","author":"T Mok","year":"2020","unstructured":"Mok T, Camidge DR, Gadgeel SM, Rosell R, Dziadziuszko R, Kim DW, et al. Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study. Ann Oncol. 2020;31(8):1056\u201364.","journal-title":"Ann Oncol"},{"issue":"7","key":"2646_CR21","first-page":"429","volume":"12","author":"MM Awad","year":"2014","unstructured":"Awad MM, Shaw AT. ALK inhibitors in non-small cell lung cancer: crizotinib and beyond. Clin Adv Hematol Oncol. 2014;12(7):429\u201339.","journal-title":"Clin Adv Hematol Oncol"},{"issue":"2","key":"2646_CR22","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/S1470-2045(15)00488-X","volume":"17","author":"AT Shaw","year":"2016","unstructured":"Shaw AT, Gandhi L, Gadgeel S, Riely GJ, Cetnar J, West H, et al. Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial. Lancet Oncol. 2016;17(2):234\u201342.","journal-title":"Lancet Oncol"},{"issue":"24","key":"2646_CR23","doi-asserted-by":"publisher","first-page":"2866","DOI":"10.1200\/JCO.2015.65.5936","volume":"34","author":"L Crino","year":"2016","unstructured":"Crino L, Ahn MJ, De Marinis F, Groen HJ, Wakelee H, Hida T, et al. Multicenter phase II study of whole-body and intracranial activity with ceritinib in patients with ALK-rearranged non-small-cell lung cancer previously treated with chemotherapy and crizotinib: results from ASCEND-2. J Clin Oncol. 2016;34(24):2866\u201373.","journal-title":"J Clin Oncol"},{"issue":"12","key":"2646_CR24","doi-asserted-by":"publisher","first-page":"2916","DOI":"10.1158\/1535-7163.MCT-16-0282","volume":"15","author":"DD Wang","year":"2016","unstructured":"Wang DD, Chen Y, Chen ZB, Yan FJ, Dai XY, Ying MD, et al. CT-707, a novel FAK inhibitor, synergizes with cabozantinib to suppress hepatocellular carcinoma by blocking cabozantinib-induced FAK activation. Mol Cancer Ther. 2016;15(12):2916\u201325.","journal-title":"Mol Cancer Ther"},{"issue":"8","key":"2646_CR25","doi-asserted-by":"publisher","first-page":"655","DOI":"10.2174\/1568009618666181031152140","volume":"19","author":"C Liang","year":"2019","unstructured":"Liang C, Zhang N, Tan Q, Liu S, Luo R, Wang Y, et al. CT-707 overcomes resistance of crizotinib through activating PDPK1-AKT1 pathway by targeting FAK. Curr Cancer Drug Targets. 2019;19(8):655\u201365.","journal-title":"Curr Cancer Drug Targets"},{"issue":"4","key":"2646_CR26","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1111\/1759-7714.12613","volume":"9","author":"X Du","year":"2018","unstructured":"Du X, Shao Y, Qin HF, Tai YH, Gao HJ. ALK-rearrangement in non-small-cell lung cancer (NSCLC). Thorac Cancer. 2018;9(4):423\u201330.","journal-title":"Thorac Cancer"},{"issue":"13","key":"2646_CR27","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1056\/NEJMoa1311107","volume":"370","author":"AT Shaw","year":"2014","unstructured":"Shaw AT, Kim DW, Mehra R, Tan DS, Felip E, Chow LQ, et al. Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med. 2014;370(13):1189\u201397.","journal-title":"N Engl J Med"},{"issue":"12","key":"2646_CR28","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1016\/S1470-2045(16)30392-8","volume":"17","author":"SN Gettinger","year":"2016","unstructured":"Gettinger SN, Bazhenova LA, Langer CJ, Salgia R, Gold KA, Rosell R, et al. Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1\/2 trial. Lancet Oncol. 2016;17(12):1683\u201396.","journal-title":"Lancet Oncol"},{"issue":"7","key":"2646_CR29","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1016\/S1470-2045(13)70142-6","volume":"14","author":"T Seto","year":"2013","unstructured":"Seto T, Kiura K, Nishio M, Nakagawa K, Maemondo M, Inoue A, et al. CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study. Lancet Oncol. 2013;14(7):590\u20138.","journal-title":"Lancet Oncol"},{"issue":"5","key":"2646_CR30","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1517\/17425255.2015.1021685","volume":"11","author":"G Hamilton","year":"2015","unstructured":"Hamilton G, Rath B, Burghuber O. Pharmacokinetics of crizotinib in NSCLC patients. Expert Opin Drug Metab Toxicol. 2015;11(5):835\u201342.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"10","key":"2646_CR31","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/S1470-2045(14)70362-6","volume":"15","author":"SM Gadgeel","year":"2014","unstructured":"Gadgeel SM, Gandhi L, Riely GJ, Chiappori AA, West HL, Azada MC, et al. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1\/2 study. Lancet Oncol. 2014;15(10):1119\u201328.","journal-title":"Lancet Oncol"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-022-02646-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-022-02646-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-022-02646-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T13:52:42Z","timestamp":1669297962000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedicine.biomedcentral.com\/articles\/10.1186\/s12916-022-02646-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,23]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["2646"],"URL":"https:\/\/doi.org\/10.1186\/s12916-022-02646-0","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,23]]},"assertion":[{"value":"12 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Ethics Committee of the National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College (Permission No.15-139\/1066); the Ethics Committee of Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College (Permission No.HS2017007); and the Ethics Committee of Tianjin Medical University Cancer Institute & Hospital (Permission No.E2018101) and conducted according to the Declaration of Helsinki, Guidelines for Good Clinical Practice, and local laws and regulations. All patients provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Yinghui Sun is an employee of Shouyao Holdings (Beijing) Co., Ltd, Beijing, China. The remaining authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"453"}}